The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Value Expansion Is Expected For The Generic Pharmaceuticals Contract Manufacturing Market Over The Forecast Period?
The generic pharmaceuticals contract manufacturing market has shown substantial growth in recent years. It is anticipated to expand from $66.82 billion in 2025 to $71.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.2%. Historically, this growth can be ascribed to a shortage of contract manufacturing choices, a reliance on internal generic drug production, an escalating demand for off-patent APIs, a greater number of generic drug approvals, and cost constraints affecting pharmaceutical companies.
The generic pharmaceuticals contract manufacturing market is poised for significant expansion in the coming years. Its valuation is projected to reach $93.56 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.9%. This anticipated growth stems from several factors, including the rising global demand for generic medications, the expansion of contract manufacturing organizations (CMOs), the implementation of advanced formulation technologies, an increasing focus on biologics and complex generics, and strengthened cross-border regulatory collaborations. Noteworthy trends during this period are expected to encompass increased outsourcing of generic drug manufacturing, an emphasis on cost-efficient production and packaging solutions, the expansion of services for injectable and tablet manufacturing, enhanced regulatory support and compliance services, and a surge in licensing and technology transfer agreements for generic products.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25771&type=smp
What Influential Factors Are Boosting The Generic Pharmaceuticals Contract Manufacturing Market Demand?
The escalating need for biosimilars is anticipated to drive the expansion of the generic pharmaceuticals contract manufacturing market moving forward. Biosimilars are biologic medical products that exhibit a high degree of similarity to already approved reference biologics, showing no clinically significant differences in safety, purity, or potency. The increasing demand for biosimilars is primarily attributed to their capacity to offer cost-effective alternatives to expensive biologic drugs, thereby enhancing the accessibility of advanced treatments for patients and healthcare systems. Generic pharmaceuticals contract manufacturing supports biosimilars by providing economical, large-scale production capabilities and the necessary regulatory expertise to expedite market entry and ensure consistent quality. For instance, in January 2023, as per Cardinal Health Inc., a US-based healthcare company, the U.S. had 33 biosimilar products approved by the FDA as of January 2022, with 21 of them available on the market. By 2023, the total number of FDA-approved biosimilars had climbed to 40, with 25 becoming commercially available. Thus, the growing demand for biosimilars is a key factor propelling the growth of the generic pharmaceuticals contract manufacturing market.
What Key Segment Areas Are Included In The Generic Pharmaceuticals Contract Manufacturing Market Assessment?
The generic pharmaceuticals contract manufacturing market covered in this report is segmented –
1) By Drug Type: Branded Generics, Unbranded Generics
2) By Product Type: Pharmaceutical Active Pharmaceutical Ingredients, Formulations, Capsules, Tablets, Injectables
3) By Route Of Administration: Oral, Parenteral, Topical, Other Routes Of Administration
4) By Application: Oncology, Immunology, Antidiabetic, Neurology, Anticoagulants, Cardiovascular, Respiratory, Pain, Human Immunodeficiency Virus Antivirals
5) By End-User Industry: Pharmaceutical Companies, Contract Research Organizations, Biotechnology Companies, Generic Drug Manufacturers
Subsegments:
1) By Branded Generics: Contract Development of Branded Formulations, Branded Generic Tablet Manufacturing, Branded Injectable Manufacturing, Packaging and Labeling for Branded Generics, Regulatory Support For Branded Generics
2) By Unbranded Generics: Bulk Manufacturing of Off-Patent Active Pharmaceutical Ingredients, Generic Tablet Or Capsule Production, Parenteral Or Injectable Generic Manufacturing, Cost-Efficient Packaging for Unbranded Products, Licensing And Tech Transfer for Generic Products
Which Trends Are Guiding The Development Of The Generic Pharmaceuticals Contract Manufacturing Market?
Leading firms within the generic pharmaceutical contract manufacturing market are broadening their service offerings through the creation of specialized subsidiaries, addressing the increasing need for outsourced development and manufacturing capabilities. This strategic initiative to set up focused subsidiaries empowers organizations to optimize the manufacturing of active pharmaceutical ingredients (APIs), thereby guaranteeing adherence to regulations, capacity for growth, and efficient operations throughout the entire drug development process. As an illustration, in July 2025, Lupin, an India-based generic pharmaceutical company, unveiled its new subsidiary, Lupin Manufacturing Solutions (LMS), with the aim of penetrating the contract development and manufacturing organization (CDMO) market. This specialized division is designed to facilitate the development, production, and distribution of APIs for pharmaceutical partners worldwide. Backed by a leadership team proficient in both biotechnology and pharmaceuticals, this subsidiary is well-equipped to provide premium contract services, assisting pharmaceutical enterprises in shortening their time-to-market while upholding regulatory compliance and cost-effectiveness.
Who Are The Firms Contributing To The Generic Pharmaceuticals Contract Manufacturing Market Ecosystem?
Major companies operating in the generic pharmaceuticals contract manufacturing market are WuXi AppTec Co. Ltd., Recipharm AB, Siegfried Holding AG, Curia Global Inc., Piramal Pharma Solutions, Laurus Labs Limited., Cambrex Corp., Alcami Corp. Inc, Neuland Laboratories Limited.
Access The Complete Generic Pharmaceuticals Contract Manufacturing Market Report:
Which Area Represents The Largest Portion Of The Generic Pharmaceuticals Contract Manufacturing Market?
North America was the largest region in the generic pharmaceuticals contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generic pharmaceuticals contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Generic Pharmaceuticals Contract Manufacturing Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=25771&type=smp
Browse Through More Reports Similar to the Global Generic Pharmaceuticals Contract Manufacturing Market 2026, By The Business Research Company
Pharmaceutical Contract Developments And Manufacturing Organization Cmo Market Report 2026
Biopharmaceuticals Contract Manufacturing Market Report 2026
Pharmaceutical Contract Packaging Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model